S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Abou-Alfa
    Abou-Alfa
  3. Drilon
    Drilon
  4. Motzer
    Motzer
  5. Antal
    Antal
  6. Berman
    Berman
  7. Cohen
    Cohen
  8. Friedman
    Friedman
  9. Hay
    Hay
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (19)
  2. Sloan Kettering Institute Postdocs (15)
  3. Molecular Imaging and Therapy Service (12)
  4. Radiology, Department of (12)
  5. Solid Tumor Oncology Division (12)
  6. Gastrointestinal Oncology Service (7)
  7. Center for Hematologic Malignancies (6)
  8. Hematologic Malignancies, Division of (6)
  9. Population Sciences Research Program (4)
  10. Genitourinary Oncology Service (3)
Search Within
  1. "2019"
Formats
  1. Meeting Abstract (25)
  2. Review (9)
  3. Journal Article (5)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (19)
  2. Sloan Kettering Institute Postdocs (15)
  3. Molecular Imaging and Therapy Service (12)
  4. Radiology, Department of (12)
  5. Solid Tumor Oncology Division (12)
  6. Gastrointestinal Oncology Service (7)

More Groups

People
  1. Lisa Bodei (12)
  2. Ghassan Abou-Alfa (4)
  3. Alexander Drilon (2)
  4. Robert Motzer (2)
  5. Alexandra Joyner (1)
  6. Alexandre Wojcinski (1)

More People

Years
  1. 2019 (40)
Publications
  1. Oncology Research and Treatment (16)
  2. Neuroendocrinology (14)
  3. Hormone Research in Paediatrics (3)
  4. Journal of Vascular Research (2)
  5. Pathobiology (2)
  6. Acta Haematologica (1)

More Publications

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy: Results from a phase III study (TAGS)
    Meeting Abstract

    Thuss-Patience, P.; Lorenzen, S.; Ettrich, T.; Karthaus, M.; Ilson, D. H.; Prokharau, A.; Arkenau, H. T.; Ghidini, M.; Fujitani, K.; Van Cutsem, E.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Association of PD-L1 combined positive score (CPS) and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)
    Meeting Abstract

    Haag, G.; Lei, M.; Siemers, N.; Pandya, D.; Chang, H.; Sanchez, T.; Dorange, C.; Harbison, C.; Szabo, P.; Janjigian, Y.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Association of adverse events (AEs) with efficiacy outcomes for Cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase 3 CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; Cicin, I.; Bolondi, L.; Klümpen, H. J.; Chan, S. L.; Dadduzio, V.; Milwee, S.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Tumor cell-intrinsic activity of the RNA receptor RIG-I promotes checkpoint inhibitor-mediated anticancer immunity
    Meeting Abstract

    Heidegger, S.; Wintges, A.; Stritzke, F.; Bek, S.; Steiger, K.; Winter, C.; Rad, R.; van den Brink, M. R. M.; Ruland, J.; Bassermann, F.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Quality-adjusted life years accrued with cabozantinib in patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Mollon, P.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Baron, A. D.; Benzaghou, F.; Valcheva, V.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of 12 mg/d lenvatinib (LEN) in patients with unresectable hepatocellular carcinoma (uHCC) and bodyweight (bw) >80 kg in REFLECT
    Meeting Abstract

    Vogel, A.; Kudo, M.; Cheng, A. L.; Sung, M. W.; Finn, R. S.; Lin, A. Y.; Abou-Alfa, G. K.; Alsina, A.; Breder, V.; Tebbutt, N.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Ibrutinib treatment in Waldenström's macroglobulinemia (WM): Follow-up results of the phase 3 iNNOVATE™ study
    Meeting Abstract

    Buske, C.; Tedeschi, A.; Trotman, J.; Garcia-Sanz, R.; Macdonald, D.; Leblond, V.; Mahe, B.; Herbaux, C.; Tam, C. S.; Palomba, M. L.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Integrated population pharmacokinetic (PopPK) modeling of cabozantinib (C) in patients (pts) with various cancer types including advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Geißler, M.; Nguyen, L. T.; Chapel, S.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Kelley, R. K.; Abou-Alfa, G. K.; Lacy, S.
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC)
    Meeting Abstract

    von Amsberg, G.; Balar, A. V.; Dreicer, R.; Loriot, Y.; Perez-Gracia, J. L.; Hoffman-Censits, J. H.; Petrylak, D. P.; van der Heijden, M. S.; Shen, X.; Ding, B.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save